Trial Profile

A phase 2 andomized, double-blind, parallel-group, multicenter study to evaluate safety, pharmacodynamics (PD), and efficacy of cenerimod in japanese patients with moderate to severe systemic lupus erythematosus (SLE)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 26 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

26 Aug 2024 New trial record
23 Aug 2024 Results published in the Viatris Media Release.
23 Aug 2024 According to Viatris media release,the company announced that the ACT-333441 study was accepted as a late-breaking abstract and was presented during an oral presentation at the 26th Asia-Pacific League of Associations for Rheumatology (APLAR) Annual Congress held on August 21 to 25, 2024, in Suntec, Singapore.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com